Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

IOVA
Iovance Biotherapeutics, Inc. Common Stock
stock NASDAQ

At Close
Dec 26, 2025 3:59:53 PM EST
2.85USD-0.871%(-0.02)8,109,498
0.00Bid   0.00Ask   0.00Spread
Pre-market
Dec 26, 2025 9:28:30 AM EST
2.93USD+2.091%(+0.06)96,600
After-hours
Dec 26, 2025 4:53:30 PM EST
2.83USD-0.527%(-0.02)4,881
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
10:17AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 28, 2022   Benzinga
08:11AM EST  Stifel Upgrades Iovance Biotherapeutics to Buy, Raises Price Target to $25   Benzinga
Jan 21, 2022
05:15PM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on January 21, 2022 (the Date of Grant), the Company approved the grant of inducement stock options covering an aggregate of 117,000 shares of Iovances common stock to thirteen new non-executive employees.   GlobeNewswire Inc
Jan 10, 2022
08:00AM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Raj K. Puri, M.D., Ph.D., will join the Company as Executive Vice President, Regulatory Strategy and Translational Medicine. Dr. Puri will begin his employment with the Company toward the end of the first quarter of 2022.   GlobeNewswire Inc
Jan 7, 2022
04:03PM EST  Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR   Benzinga
04:01PM EST  TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped from Australia   GlobeNewswire Inc
Jan 6, 2022
05:38PM EST  Iovance Biotherapeutics to Present at the 40th Annual J.P. Morgan   GlobeNewswire Inc
Dec 28, 2021
11:30AM EST  Iovance Biotherapeutics Option Alert: Jan 21 $22.5 Calls at the Ask: 1450 @ $1.15 vs 5222 OI; Ref=$20.1079   Benzinga
Dec 17, 2021
05:15PM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on December 16, 2021 (the Date of Grant), the Company approved the grant of inducement stock options covering an aggregate of 107,900 shares of Iovances common stock to eleven new non-executive employees.   GlobeNewswire Inc
Dec 7, 2021
08:41AM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced participation in the following conferences in December:   GlobeNewswire Inc
Nov 19, 2021
05:15PM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on November 18, 2021 (the Date of Grant), the Company approved the grant of inducement stock options covering an aggregate of 168,575 shares of Iovances common stock to seven new non-executive employees.   GlobeNewswire Inc
Nov 13, 2021
04:30PM EST  Tumor Infiltrating Lymphocyte (TIL) Cell Therapyin Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Nave Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melanoma with 30% Complete Response (CR) and 39% in Head and Neck Cancer   GlobeNewswire Inc
Nov 12, 2021
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:18AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:17AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:16AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:15AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:14AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:12AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:10AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:09AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:01AM EST  21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC)   GlobeNewswire Inc
Nov 9, 2021
11:47AM EST  Iovance Biotherapeutics Announces Clinical Data For Tumor Infiltrating Lymphocyte (TIL) Cell Therapy In Multiple Solid Tumors At Society For Immunotherapy Of Cancer (SITC) Annual Meeting   Benzinga
08:54AM EST  TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Nave Cervical Cancer, Melanoma, and Head and Neck Cancer   GlobeNewswire Inc
Nov 8, 2021
04:01PM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences in November:   GlobeNewswire Inc
Nov 5, 2021
09:37AM EDT  HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $43   Benzinga
09:23AM EDT  Iovance Biotherapeutics Q3 EPS $(0.55) Misses $(0.53) Estimate   Benzinga
Nov 4, 2021
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 25, 2021
04:01PM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter financial results on Thursday, November 4, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.   GlobeNewswire Inc
Oct 21, 2021
12:24PM EDT  Iovance Shares Move Higher; November $30 Calls Active   Benzinga
Oct 18, 2021
04:01PM EDT  Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumabin Immune-Checkpoint Inhibitor Nave Patients with Advanced Cancers   GlobeNewswire Inc
Oct 1, 2021
08:48AM EDT  Iovance Biotherapeutics To Present Clinical Data For Tumor Infiltrating Lymphocyte Cell Therapies Across Multiple Solid Tumors And Treatment Settings At The Society For Immunotherapy Of Cancer's 36th Annual Meeting Nov. 13   Benzinga
08:47AM EDT  Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumabin Immune Checkpoint Inhibitor-Nave Patients with Advanced Cancers   GlobeNewswire Inc
Sep 28, 2021
05:01PM EDT  Iovance Biotherapeutics Celebrates Grand Opening Of Iovance Cell Therapy Center (iCTC) In The Philadelphia Navy Yard   Benzinga
05:00PM EDT  Ribbon Cutting to be Led by Patient Advocacy Organizations, Caregivers, and Key Stakeholders   GlobeNewswire Inc
Sep 23, 2021
07:47AM EDT  Iovance Biotherapeutics Begins Clinical Supply Of TIL Cell Therapy Manufactured At Iovance Cell Therapy Center   RTTNews
07:37AM EDT  Iovance Biotherapeutics Initiates Clinical Supply Of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured At Iovance Cell Therapy Center (iCTC)   Benzinga
07:30AM EDT  Iovance Biotherapeutics Initiates Clinical Supply of   GlobeNewswire Inc
Sep 9, 2021
03:54PM EDT  Iovance Biotherapeutics Option Alert: Oct 15 $25 Calls Sweep (23) above Ask!: 162 @ $2.387 vs 191 OI; Earnings 11/4 After Close [est] Ref=$24.1   Benzinga
Aug 5, 2021
04:51PM EDT  Iovance Biotherapeutics Q2 EPS $(0.53) Misses $(0.51) Estimate   Benzinga
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Jul 19, 2021
04:30PM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 5, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.   GlobeNewswire Inc
Jun 29, 2021
03:38PM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical data for LN-145 TIL therapy in non-small cell lung cancer today at 4:30 p.m. ET.   GlobeNewswire Inc
10:14AM EDT  Shares of biotechnology company Iovance Biotherapeutics, Inc. (IOVA) are down 4 percent on Tuesday's trading as the company released clinical data on its tumor infiltrating lymphocyte or TIL therapy LN-145 conducted on patients with metastatic non-small cell lung cancer.   RTTNews
09:12AM EDT  Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer Patients   Benzinga
06:35AM EDT  Iovance Biotherapeutics Announces Clinical Data For LN-145 In Non-Small Cell Lung Cancer   RTTNews
06:32AM EDT  Iovance Biotherapeutics Announces Clinical Data For LN-145 ; Showed 21.4% Overall Response Rate In Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer Patients Following One Or More Prior Systemic Therapies Including Immunotherapy   Benzinga
06:30AM EDT  21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic TherapiesIncluding Immunotherapy   GlobeNewswire Inc
Jun 28, 2021
07:10PM EDT  BIOMEA Fusion Strengthens its Executive Team with Appointment of   GlobeNewswire Inc
Jun 24, 2021
01:39PM EDT  Iovance Biotherapeutics Option Alert: Jul 16 $25 Calls Sweep (37) near the Ask: 1156 @ $2.65 vs 7028 OI; Earnings 8/5 After Close [est] Ref=$25.935   Benzinga
Jun 7, 2021
08:27AM EDT  Iovance's Lifileucel Shows Meaningful Increase in Response Time with Primary Anti-PD-1 Resistance in Melanoma Trial   Benzinga
Jun 6, 2021
09:32AM EDT  Iovance Biotherapeutics Announced 33-month Follow Up Data for Lifileucel in Advanced Melanoma at Asco 2021; Said Median Duration of Response Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study   Benzinga
09:24AM EDT  Median Duration of Response (DOR) Not Reached at 33.1 Monthsof Median Study Follow Up in Cohort 2 in C-144-01 Study   GlobeNewswire Inc
Jun 4, 2021
09:12AM EDT  Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting   Benzinga
09:09AM EDT  86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Nave Advanced Melanoma Patients in IOV-COM-202 Clinical Study   GlobeNewswire Inc
Jun 1, 2021
07:30AM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual conferences in June:   GlobeNewswire Inc
May 24, 2021
08:20AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
07:03AM EDT  Oppenheimer Maintains Outperform on Iovance Biotherapeutics, Lowers Price Target to $38   Benzinga
01:46AM EDT  Why Cathie Wood Is Bullish On Iovance Biotherapeutics (IOVA)   Benzinga
May 20, 2021
04:03PM EDT  (IOVA) Investors With Losses and Persons Who May Assist Firm's Investigation Into Possible Securities Law Violations to Contact Its Attorneys Now   PR Newswire
12:20PM EDT  Iovance Shares Jump After Lifileucel Achieves 86% Response Rate In Melanoma Trial   Benzinga
11:09AM EDT  Iovance Biotherapeutics, Inc. (IOVA) shares are trading higher on Thursday morning. The shares have been gaining since Wednesday as the company announced that it will continue with the first potential biologics license application for lifileucel, as it received regulatory feedback from FDA.   RTTNews
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2021   Benzinga
08:27AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks   Benzinga
08:17AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
06:48AM EDT  Piper Sandler Downgrades Iovance Biotherapeutics to Neutral, Lowers Price Target to $18   Benzinga
May 19, 2021
06:36PM EDT  Hagens Berman urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Hagens Berman also invites persons who may be able to assist the firms investigation to contact the firm.   GlobeNewswire Inc
05:25PM EDT  Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021   Benzinga
05:05PM EDT  86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Nave Advanced Melanoma Patients in IOV-COM-202 Clinical Study   GlobeNewswire Inc
02:52PM EDT  Mid-Afternoon Market Update: Dow Falls 1%; Iovance Biotherapeutics Shares Plunge   Benzinga
12:19PM EDT  Mid-Day Market Update: Crude Oil Down 5%; Reata Pharmaceuticals Shares Jump   Benzinga
10:27AM EDT  Mid-Morning Market Update: Markets Open Lower; Target Profit Beats Estimates   Benzinga
08:26AM EDT  Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $51   Benzinga
07:46AM EDT  JMP Securities Maintains Market Outperform on Iovance Biotherapeutics, Lowers Price Target to $43   Benzinga
07:30AM EDT  The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics   Benzinga
07:10AM EDT  Oppenheimer Maintains Outperform on Iovance Biotherapeutics, Lowers Price Target to $51   Benzinga
07:04AM EDT  Barclays Maintains Overweight on Iovance Biotherapeutics, Lowers Price Target to $40   Benzinga
06:22AM EDT  HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $46   Benzinga
May 18, 2021
05:18PM EDT  Shares of Iovance Biotherapeutics, Inc. (IOVA) slipped over 10% on Tuesday extended session after the late-stage biotechnology company developing cancer therapies announced receipt of regulatory feedback from the U.S. Food and Drug Administration (FDA) regarding its potency assays for lifileucel.   RTTNews
04:37PM EDT  Iovance Biotherapeutics Provides Regulatory Update For Lifileucel Potency Assays   Benzinga
04:30PM EDT  Iovance Biotherapeutics Provides Regulatory Update for Lifileucel   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 12, 2021
04:51PM EDT  Iovance Biotherapeutics Highlights Publication Of Clinical Data For Cohort 2 In Iovance C-144-01 Study In Journal Of Clinical Oncology   Benzinga
04:36PM EDT  Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up   GlobeNewswire Inc
May 6, 2021
04:39PM EDT  Iovance Biotherapeutics Q1 EPS $(0.51) Misses $(0.49) Estimate   Benzinga
04:01PM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported first quarter 2021 financial results and corporate updates.   GlobeNewswire Inc
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
May 5, 2021
11:39AM EDT  Iovance Biotherapeutics Shares See Volume; Hearing Wells Fargo Issues Note On Data For Co's KEYTRUDA Plus Low-Dose YERVOY   Benzinga
Apr 28, 2021
10:52AM EDT  Iovance Biotherapeutics To Present Clinical Data For Lifileucel In Advanced Melanoma At ASCO 2021 Annual Meeting   Benzinga
10:50AM EDT  Iovance Biotherapeutics to Present Clinical Data for   GlobeNewswire Inc
Apr 27, 2021
04:01PM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 6, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.   GlobeNewswire Inc
Apr 16, 2021
10:08AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021   Benzinga
06:51AM EDT  Goldman Sachs Initiates Coverage On Iovance Biotherapeutics with Buy Rating, Announces Price Target of $97   Benzinga
Apr 9, 2021
07:04AM EDT  Iovance Biotherapeutics Highlights Clinical Data Updates For Its Advance Melanoma Candidate During American Association For Cancer Research Annual Meeting Apr. 10 At 4:45 p.m. EDT   Benzinga
07:00AM EDT  Median Duration of Response Not Reached at 28.1 Monthsof Median Study Follow Up in Cohort 2 of C-144-01 Study   GlobeNewswire Inc
Apr 1, 2021
10:05AM EDT  Seeing Iovance Block Trade Of 2M Shares At $31/Share   Benzinga
Mar 15, 2021
04:01PM EDT  Iovance Biotherapeutics Names Igor Bilinsky COO   Benzinga
04:01PM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky, Ph.D., as Chief Operating Officer, effective today. Dr. Bilinsky brings more than 20 years of biotechnology industry experience as a senior executive and consultant, including public companies.   GlobeNewswire Inc
Mar 10, 2021
05:28PM EST  Iovance Biotherapeutics to Present Updated Clinical Data for Tumor   GlobeNewswire Inc
Mar 8, 2021
02:20PM EST  Iovance Biotherapeutics shares were trading higher after HC Wainwright & Co. upgraded the stock from Neutral to Buy and announced a price target of $50 per share.   Benzinga
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021   Benzinga
06:10AM EST  HC Wainwright & Co. Upgrades Iovance Biotherapeutics to Buy, Announces $50 Price Target   Benzinga
Mar 1, 2021
04:01PM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcare conferences:   GlobeNewswire Inc
Feb 25, 2021
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 18, 2021
07:30AM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EST.   GlobeNewswire Inc
Jan 19, 2021
08:56AM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcare conferences:   GlobeNewswire Inc
Dec 28, 2020
07:30AM EST  Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan   GlobeNewswire Inc
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
06:25AM EST  HC Wainwright & Co. Downgrades Iovance Biotherapeutics to Neutral   Benzinga
Dec 14, 2020
07:06AM EST  Iovance Biotherapeutics Appoints Jean-Marc Bellemin As CFO   RTTNews
07:03AM EST  Iovance Biotherapeutics Appoints Jean-Marc Bellemin As Chief Financial Officer   Benzinga
07:00AM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Jean-Marc Bellemin as Chief Financial Officer, effective today. Mr. Bellemin brings 27 years of industry experience in finance, including public companies.   GlobeNewswire Inc
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Nov 30, 2020
07:22AM EST  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November:   GlobeNewswire Inc
Nov 9, 2020
08:28AM EST  Iovance Biotherapeutics Presents Clinical Data In Head And Neck Cancer At Society For Immunotherapy Of Cancer (SITC) 35th Annual Meeting   Benzinga
08:00AM EST  44.4% Overall Response Rate (ORR) and Median Duration of Response (DOR) Not Reached at 8.6 Months of Study Follow Up   GlobeNewswire Inc
07:05AM EST  JMP Securities Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $45   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
04:02PM EST  Iovance Biotherapeutics Q3 EPS $(0.40) Beats $(0.46) Estimate   Benzinga
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 30, 2020
07:00AM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter 2020 financial results on Thursday, Nov. 5, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EST.   GlobeNewswire Inc
Oct 28, 2020
07:45AM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November:   GlobeNewswire Inc
Oct 15, 2020
07:38AM EDT  Wells Fargo Maintains Equal-Weight on Iovance Biotherapeutics, Raises Price Target to $35   Benzinga
Oct 14, 2020
05:03PM EDT  Iovance Biotherapeutics Reports Will Present Clinical Data In Head And Neck Cancer At Society For Immunotherapy Of Cancer Meeting Nov. 9-14   Benzinga
05:01PM EDT  Iovance Biotherapeutics to Present Clinical Data in Head and Neck   GlobeNewswire Inc
Oct 9, 2020
09:00PM EDT  Bragar Eagel & Squire, P.C. Is Investigating Evolus, Lizhi,   GlobeNewswire Inc
Oct 8, 2020
05:49PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
Oct 6, 2020
11:10AM EDT  Iovance Biotherapeutics Option Alert: Dec 18 $30 Calls Sweep (25) near the Ask: 138 @ $2.5 vs 39 OI; Earnings 11/2 After Close [est] Ref=$28.865   Benzinga
10:15AM EDT  Mid-Morning Market Update: Markets Rise; Paychex Beats Q1 Views   Benzinga
10:14AM EDT  Benzinga's Top Upgrades, Downgrades For October 6, 2020   Benzinga
10:08AM EDT  Iovance Biotherapeutics, Inc. (IOVA) shares are sliding more than 16 percent on Tuesday morning trade as the company expects a delay in its BLA submission for its trial using lifileucel.   RTTNews
08:43AM EDT  Barclays Maintains Overweight on Iovance Biotherapeutics, Lowers Price Target to $36   Benzinga
08:23AM EDT  Wells Fargo Downgrades Iovance Biotherapeutics to Equal-Weight, Lowers Price Target to $29   Benzinga
08:08AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
07:00AM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences.   GlobeNewswire Inc
06:32AM EDT  HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $46   Benzinga
05:08AM EDT  Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $50   Benzinga
Oct 5, 2020
06:14PM EDT  After Market Hours: Alteryx, GlycoMimetics, Spartan Energy   RTTNews
04:03PM EDT  Iovance Biotherapeutics Reports Co. And FDA 'have not been able to agree on the required potency assays to fully define its TIL therapy'; Says BLA Submission For Lifileucel Now Anticipated For 2021   Benzinga
04:01PM EDT  Iovance Biotherapeutics Provides Update for Lifileucel in   GlobeNewswire Inc
Sep 8, 2020
03:15PM EDT  Iovance Biotherapeutics Option Alert: Oct 16 $35 Calls Sweep (5) near the Ask: 110 @ $3.601 vs 700 OI; Earnings 11/2 After Close [est] Ref=$31.8   Benzinga
01:40PM EDT  Iovance Biotherapeutics Option Alert: Oct 16 $40 Calls Sweep (2) near the Ask: 382 @ $2.0 vs 373 OI; Earnings 11/2 After Close [est] Ref=$31.34   Benzinga
Aug 7, 2020
08:50AM EDT  Chardan Capital Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $53   Benzinga
07:30AM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the BTIG Biotechnology Conference 2020 (Virtual) on August 11, 2020 at 2:30pm ET.   GlobeNewswire Inc
Aug 6, 2020
04:04PM EDT  Iovance Biotherapeutics Q2 EPS $(0.47) Beats $(0.53) Estimate   Benzinga
08:09AM EDT  Avid Biosciences Reports Selected By Iovance Biotherapeutics To Lead Process Development Through CGMP Manufacturing Of IOV-3001   Benzinga
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
Jul 23, 2020
07:30AM EDT  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC